Metronome LLC v. Well Care Botanicals: Cannabis Patent Case Ends in Voluntary Dismissal

Case Overview

The Parties

The Patent at Issue

This case centered on a key patent covering formulation technology:

• • Patent Number: US10653736B2
• • Application Number: US16/257389
• • Technology Area: Topical treatments incorporating Cannabis sp. derived botanical drug products
• • Classification: Pharmaceutical/botanical formulation

US10653736B2 covers formulation technology relating to cannabis-derived botanical drug products applied topically. The patent’s claims likely address specific concentration ranges, delivery mechanisms, or active ingredient combinations — elements critical to claim construction in pharmaceutical patent litigation.

The Accused Products

The products at issue were described as topical treatments incorporating cannabis-derived botanical drug products — a broad category encompassing CBD-infused creams, salves, balms, and transdermal patches that have proliferated in consumer wellness markets since the 2018 Farm Bill legalized hemp-derived cannabinoids federally.

Legal Representation

Both firms represent specialized IP boutique practices, a common representation pattern in mid-market patent assertion cases in the cannabis sector.

• • Plaintiff’s Counsel: Antranig Niaz Garibian, Garibian Law Offices, PC
• • Defendant’s Counsel: John Hoon Choi, John H. Choi & Associates, LLC

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the District of New Jersey — a jurisdiction with significant pharmaceutical and life sciences patent docket experience, making it a strategically logical venue for cannabis-adjacent pharmaceutical patent claims.

The 154-day duration from filing to closure is notably brief. It suggests the matter likely did not advance to claim construction proceedings, expert discovery, or any substantive dispositive motion practice. The rapid closure — without disclosed rulings on motions to dismiss, invalidity challenges, or infringement findings — is consistent with an early-stage resolution, whether through settlement negotiation, licensing agreement, or a unilateral strategic decision by Metronome to withdraw its claims.

No chief judge assignment data is available in the public record for this matter, and specific interim procedural milestones were not disclosed in available case documentation.

The Verdict & Legal Analysis

Outcome

On August 19, 2025, the District Court of New Jersey entered an Order Granting Plaintiff’s Notice of Voluntary Dismissal With Prejudice in Metronome LLC v. Well Care Botanicals LLC. The court granted Metronome LLC’s own motion, formally terminating the litigation.

No damages award was issued. No injunctive relief was granted or denied on the merits. The specific financial terms — if any confidential resolution accompanied the dismissal — were not publicly disclosed.

Understanding Dismissal With Prejudice

A voluntary dismissal with prejudice under Federal Rule of Civil Procedure 41(a) carries significant legal weight: it bars Metronome from re-filing the same infringement claims against Well Care Botanicals based on the same patent and accused products. This is a permanent closure on those specific claims — not a procedural pause.

This distinguishes it from a dismissal without prejudice, which would preserve the plaintiff’s right to refile. The with-prejudice designation, initiated by the plaintiff itself, suggests one of several scenarios:

1. Confidential settlement reached — the parties resolved the dispute privately, with dismissal serving as the closing procedural step
2. Licensing agreement executed — Metronome may have obtained a licensing fee or ongoing royalty from Well Care Botanicals, rendering continued litigation unnecessary
3. Strategic withdrawal — Metronome may have assessed litigation risk, including potential invalidity counterclaims or unfavorable claim construction prospects, and elected to exit before adverse rulings could create precedent affecting its broader patent portfolio

Legal Significance

Because the case closed without a substantive court ruling on infringement, validity, or claim construction, US10653736B2 remains unscathed by adverse judicial precedent from this proceeding. This is strategically significant: Metronome’s patent exits this litigation with its claims intact and unchallengeable based on this specific case record.

For cannabis patent litigation broadly, the outcome reflects a recurring pattern — many cannabis IP cases settle or dismiss early, partly because the underlying technology intersects with complex regulatory frameworks (DEA scheduling, FDA botanical drug guidance) that create unusual invalidity arguments around prior art, utility, and public policy.

Strategic Takeaways

For Patent Holders:
Voluntary dismissal with prejudice, while seemingly a concession, can be a calibrated tool. If a licensing fee was secured, the plaintiff achieved monetization without exposing its patent to inter partes review (IPR) risk or unfavorable claim construction rulings that could undermine future assertions.

For Accused Infringers:
Well Care Botanicals’ defense posture — represented by specialized IP counsel — likely contributed to the swift resolution. Early investment in invalidity analysis, prior art searches, and claim construction positioning often accelerates favorable outcomes in pharmaceutical patent disputes.

For R&D Teams:
Companies developing cannabis topical formulations should conduct freedom-to-operate (FTO) analysis against US10653736B2 and related continuation applications. The patent’s survival through this litigation — with no adverse validity ruling — means it remains an active enforcement tool.

Industry & Competitive Implications

The cannabis topical patent space is increasingly contested. As hemp-derived CBD products have moved from niche wellness stores to mass retail channels, patent holders have become more aggressive in asserting formulation, extraction, and delivery IP against competitors.

Metronome v. Well Care Botanicals reflects broader trends:

• Increased patent assertion activity targeting mid-market cannabis brands lacking the IP litigation resources of larger pharmaceutical companies
• Early settlement patterns driven by litigation cost asymmetry — smaller cannabis companies often find licensing fees economically preferable to full litigation defense
• Portfolio risk concentration — cannabis companies that have not conducted proactive FTO reviews of formulation patents face growing exposure as the IP landscape matures

The survival of US10653736B2 without an invalidity adjudication means it remains a live threat to competitors in the cannabis topical market. Companies operating in adjacent formulation spaces — particularly those using cannabis-derived botanical drug products in topical applications — should monitor this patent and any continuation applications through the USPTO Patent Center.

The outcome also signals that Metronome LLC may continue asserting this patent against other market participants, making this case a potential bellwether for a broader enforcement campaign.

❓ Frequently Asked Questions

What patent was involved in Metronome LLC v. Well Care Botanicals LLC?

The case involved US10653736B2 (Application No. US16/257389), covering topical treatments incorporating Cannabis sp. derived botanical drug products, filed in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-01936).

Why did the plaintiff voluntarily dismiss with prejudice?

The specific reasons were not publicly disclosed. Common explanations include a confidential settlement or licensing agreement, strategic risk management to avoid adverse claim construction rulings, or assessment of invalidity exposure from potential counterclaims.

How does this case affect cannabis topical patent litigation?

The case reinforces that US10653736B2 remains valid and enforceable without adverse court findings, suggesting continued enforcement risk for companies in the cannabis topical formulation market. Companies should pursue FTO analysis and monitor Metronome LLC’s future assertion activity.